

**DESCRIPTION**

|                                       |                                                                                      |
|---------------------------------------|--------------------------------------------------------------------------------------|
| <b>Target:</b>                        | VEGFA                                                                                |
| <b>Target aliases:</b>                | VPF, VEGF, MVCD1                                                                     |
| <b>Fc isotype:</b>                    | IgG2a                                                                                |
| <b>Membrane proteome specificity:</b> | Monospecific for 6,000 membrane proteins tested                                      |
| <b>Species reactivity:</b>            | Human (Others untested)                                                              |
| <b>Extracellular epitope:</b>         | Yes                                                                                  |
| <b>Fc modifications:</b>              | C-terminal Avitag <sup>1</sup> , disabled Fc- $\gamma$ receptor binding <sup>2</sup> |
| <b>Source:</b>                        | Recombinant CHO expression; purified by Protein A chromatography                     |
| <b>Formulation:</b>                   | Endotoxin Free PBS pH 7.4, sterile-filtered                                          |
| <b>Concentration:</b>                 | 1 mg/ml                                                                              |


1. A peptide tag that can be biotinylated in vitro using the biotin ligase enzyme (BirA).
2. Mutated Fc- $\gamma$  receptor binding site to minimize non-specific antibody binding.

**VEGFA TARGET INFORMATION**


VEGF-A is a member of the PDGF/VEGF growth factor family. Specifically, VEGF-A is a disulfide-linked homodimer that binds heparin. VEGF-A is a secreted protein involved in endothelial cell proliferation and migration, angiogenesis, and vasculogenesis. Increased expression is associated with SARS-CoV-2 and POEMS syndrome as well as many tumors, and allelic variants are associated with microvascular complications of diabetes 1 and atherosclerosis. (NCBI Gene: 7422, UniProtKB/Swiss-Prot: P15692) Other names: VPF, VEGF, MVCD1

**SHIPPING AND STORAGE**

|                                 |                                                                                                  |
|---------------------------------|--------------------------------------------------------------------------------------------------|
| <b>Shipping:</b>                | Shipped at ambient temperature. Store at 4°C.                                                    |
| <b>Stability &amp; Storage:</b> | Stable for 12 months from date of receipt when stored at 4°C. Avoid repeated freeze-thaw cycles. |


**VALIDATION DATA**
**Membrane Proteome Specificity**


| Applications                  | Conditions            | Recommended concentration |
|-------------------------------|-----------------------|---------------------------|
| Flow Cytometry, Extracellular | Live, Unpermeabilized | 1 µg/ml                   |



HEK-293F cells transiently transfected with VEGFA were stained with VEGFA Monoclonal Antibody (CSB0117)(green) or isotype control antibody (gray), followed by AlexaFluor 647- conjugated anti- IgG secondary antibody. HEK-293F cells transiently transfected with an empty control vector were also stained with VEGFA Monoclonal Antibody (CSB0117)(blue).

| Applications                      | Conditions                | Recommended concentration |
|-----------------------------------|---------------------------|---------------------------|
| Immunofluorescence, Extracellular | Fixed 4% paraformaldehyde | 1 µg/ml                   |



(Left) COS-7 cells transiently transfected VEGFA were stained with VEGFA Monoclonal Antibody (CSB0117) followed by AlexaFluor 647 anti- IgG secondary antibody (red) and DAPI (blue). (Top right) COS-7 cells transiently transfected with an empty control vector stained with VEGFA Monoclonal Antibody. (Bottom right) Isotype control: COS-7 cells transfected with VEGFA and stained with control MAb.

**Applications**


Immunofluorescence, Intracellular

**Conditions**

Fixed 4 % paraformaldehyde,  
Permeabilized 0.1% Triton X-100

**Recommended concentration**

1 µg/ml



(Left) COS-7 cells transiently transfected VEGFA were permeabilized and stained with VEGFA Monoclonal Antibody (CSB0117) followed by AlexaFluor 647 anti- IgG secondary antibody (red) and DAPI (blue). (Top right) COS-7 cells transiently transfected with an empty control vector stained with VEGFA Monoclonal Antibody. (Bottom right) Isotype control: COS-7 cells transfected with {{target}} and stained with control MAb.